A citation-based method for searching scientific literature

Zhen Wang, Weixue Huang, Kaijie Zhou, Xiaomei Ren, Ke Ding. J Med Chem 2022
Times Cited: 8







List of co-cited articles
48 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.
Yangbing Li, Jiuling Yang, Angelo Aguilar, Donna McEachern, Sally Przybranowski, Liu Liu, Chao-Yie Yang, Mi Wang, Xin Han, Shaomeng Wang. J Med Chem 2019
131
37

Small-Molecule PROTACS: New Approaches to Protein Degradation.
Momar Toure, Craig M Crews. Angew Chem Int Ed Engl 2016
334
37

PROTAC targeted protein degraders: the past is prologue.
Miklós Békés, David R Langley, Craig M Crews. Nat Rev Drug Discov 2022
121
37

The history and future of targeting cyclin-dependent kinases in cancer therapy.
Uzma Asghar, Agnieszka K Witkiewicz, Nicholas C Turner, Erik S Knudsen. Nat Rev Drug Discov 2015
954
25

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
Tinghu Zhang, Nicholas Kwiatkowski, Calla M Olson, Sarah E Dixon-Clarke, Brian J Abraham, Ann K Greifenberg, Scott B Ficarro, Jonathan M Elkins, Yanke Liang, Nancy M Hannett,[...]. Nat Chem Biol 2016
173
25

Kinase Inhibitors as Underexplored Antiviral Agents.
Javier García-Cárceles, Elena Caballero, Carmen Gil, Ana Martínez. J Med Chem 2022
11
25

Discovery and resistance mechanism of a selective CDK12 degrader.
Baishan Jiang, Yang Gao, Jianwei Che, Wenchao Lu, Ines H Kaltheuner, Ruben Dries, Marian Kalocsay, Matthew J Berberich, Jie Jiang, Inchul You,[...]. Nat Chem Biol 2021
33
25

Trends in kinase drug discovery: targets, indications and inhibitor design.
Misty M Attwood, Doriano Fabbro, Aleksandr V Sokolov, Stefan Knapp, Helgi B Schiöth. Nat Rev Drug Discov 2021
114
25

Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
Jonathan Chou, David A Quigley, Troy M Robinson, Felix Y Feng, Alan Ashworth. Cancer Discov 2020
96
25


CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Shawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, Sofia Dust, Daniel G Stover, David Chi, Benjamin Primack, Shiliang Cao, Andrea J Bernhardy, Rhiannon Coulson,[...]. Cell Rep 2016
159
25

Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Victor Quereda, Simon Bayle, Francesca Vena, Sylvia M Frydman, Andrii Monastyrskyi, William R Roush, Derek R Duckett. Cancer Cell 2019
108
25

VMD: visual molecular dynamics.
W Humphrey, A Dalke, K Schulten. J Mol Graph 1996
25

Structural Basis for the Non-catalytic Functions of Protein Kinases.
Jennifer E Kung, Natalia Jura. Structure 2016
89
25

Epigenetics: a landscape takes shape.
Aaron D Goldberg, C David Allis, Emily Bernstein. Cell 2007
25

Development of selective small molecule MDM2 degraders based on nutlin.
Bo Wang, Suzhen Wu, Jin Liu, Ka Yang, Haibo Xie, Weiping Tang. Eur J Med Chem 2019
27
25

Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders.
Mette Ishoey, Someth Chorn, Natesh Singh, Martin G Jaeger, Matthias Brand, Joshiawa Paulk, Sophie Bauer, Michael A Erb, Katja Parapatics, André C Müller,[...]. ACS Chem Biol 2018
73
25

Harnessing the anti-cancer natural product nimbolide for targeted protein degradation.
Jessica N Spradlin, Xirui Hu, Carl C Ward, Scott M Brittain, Michael D Jones, Lisha Ou, Milton To, Andrew Proudfoot, Elizabeth Ornelas, Mikias Woldegiorgis,[...]. Nat Chem Biol 2019
160
25

Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications.
Nathaniel J Henning, Andrew G Manford, Jessica N Spradlin, Scott M Brittain, Erika Zhang, Jeffrey M McKenna, John A Tallarico, Markus Schirle, Michael Rape, Daniel K Nomura. J Am Chem Soc 2022
28
25

Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16.
Xiaoyu Zhang, Vincent M Crowley, Thomas G Wucherpfennig, Melissa M Dix, Benjamin F Cravatt. Nat Chem Biol 2019
159
25

Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
Marı A Maneiro, Nafsika Forte, Maria M Shchepinova, Cyrille S Kounde, Vijay Chudasama, James Richard Baker, Edward W Tate. ACS Chem Biol 2020
67
25

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
Kanak Raina, Jing Lu, Yimin Qian, Martha Altieri, Deborah Gordon, Ann Marie K Rossi, Jing Wang, Xin Chen, Hanqing Dong, Kam Siu,[...]. Proc Natl Acad Sci U S A 2016
427
25

Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs.
Michael J Bond, Ling Chu, Dhanusha A Nalawansha, Ke Li, Craig M Crews. ACS Cent Sci 2020
110
25

Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.
Bo Wang, Jin Liu, Ira Tandon, Suzhen Wu, Peng Teng, Jianhua Liao, Weiping Tang. Eur J Med Chem 2021
13
25

Exploiting the folate receptor α in oncology.
Mariana Scaranti, Elena Cojocaru, Susana Banerjee, Udai Banerji. Nat Rev Clin Oncol 2020
115
25

Design and synthesis of selective degraders of EGFRL858R/T790M mutant.
Xin Zhang, Fang Xu, Linjiang Tong, Tao Zhang, Hua Xie, Xiaoyun Lu, Xiaomei Ren, Ke Ding. Eur J Med Chem 2020
39
25

Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function.
Mai Luo, Jessica N Spradlin, Lydia Boike, Bingqi Tong, Scott M Brittain, Jeffrey M McKenna, John A Tallarico, Markus Schirle, Thomas J Maimone, Daniel K Nomura. Cell Chem Biol 2021
36
25

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras.
Honorine Lebraud, David J Wright, Christopher N Johnson, Tom D Heightman. ACS Cent Sci 2016
159
25

Targeted protein degradation: expanding the toolbox.
Matthieu Schapira, Matthew F Calabrese, Alex N Bullock, Craig M Crews. Nat Rev Drug Discov 2019
314
25

Strategies for designing proteolysis targeting chimaeras (PROTACs).
Shipeng He, Guoqiang Dong, Junfei Cheng, Ying Wu, Chunquan Sheng. Med Res Rev 2022
13
25

Aptamers as targeted therapeutics: current potential and challenges.
Jiehua Zhou, John Rossi. Nat Rev Drug Discov 2017
764
25

DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras.
Xiaoyu Zhang, Lena M Luukkonen, Christie L Eissler, Vincent M Crowley, Yu Yamashita, Michael A Schafroth, Shota Kikuchi, David S Weinstein, Kent T Symons, Brian E Nordin,[...]. J Am Chem Soc 2021
31
25

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
George M Burslem, Blake E Smith, Ashton C Lai, Saul Jaime-Figueroa, Daniel C McQuaid, Daniel P Bondeson, Momar Toure, Hanqing Dong, Yimin Qian, Jing Wang,[...]. Cell Chem Biol 2018
268
25

Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer.
Shipeng He, Fei Gao, Junhui Ma, Haoqian Ma, Guoqiang Dong, Chunquan Sheng. Angew Chem Int Ed Engl 2021
23
25

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.
Carl C Ward, Jordan I Kleinman, Scott M Brittain, Patrick S Lee, Clive Yik Sham Chung, Kenneth Kim, Yana Petri, Jason R Thomas, John A Tallarico, Jeffrey M McKenna,[...]. ACS Chem Biol 2019
117
25

Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer.
Shipeng He, Junhui Ma, Yuxin Fang, Ying Liu, Shanchao Wu, Guoqiang Dong, Wei Wang, Chunquan Sheng. Acta Pharm Sin B 2021
19
25

Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein.
Zhiwen Qi, Guliang Yang, Tao Deng, Jianmin Wang, Hao Zhou, Sergey A Popov, Elvira E Shults, Chengzhang Wang. Bioorg Chem 2021
7
28


Targeted protein degraders crowd into the clinic.
Asher Mullard. Nat Rev Drug Discov 2021
105
25

Cancer Selective Target Degradation by Folate-Caged PROTACs.
Jing Liu, He Chen, Yi Liu, Yudao Shen, Fanye Meng, H Ümit Kaniskan, Jian Jin, Wenyi Wei. J Am Chem Soc 2021
37
25


Kinase drug discovery 20 years after imatinib: progress and future directions.
Philip Cohen, Darren Cross, Pasi A Jänne. Nat Rev Drug Discov 2021
162
25


Small-Molecule Modulation of Protein Homeostasis.
George M Burslem, Craig M Crews. Chem Rev 2017
143
25

Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist's Perspective.
Laura M Luh, Ulrike Scheib, Katrin Juenemann, Lars Wortmann, Michael Brands, Philipp M Cromm. Angew Chem Int Ed Engl 2020
47
25

PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase.
Bikash Adhikari, Jelena Bozilovic, Mathias Diebold, Jessica Denise Schwarz, Julia Hofstetter, Martin Schröder, Marek Wanior, Ashwin Narain, Markus Vogt, Nevenka Dudvarski Stankovic,[...]. Nat Chem Biol 2020
43
25

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis.
Jun Wang, Xufen Yu, Weida Gong, Xijuan Liu, Kwang-Su Park, Anqi Ma, Yi-Hsuan Tsai, Yudao Shen, Takashi Onikubo, Wen-Chieh Pi,[...]. Nat Cell Biol 2022
16
25

Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2.
Zhihao Liu, Xi Hu, Qiwei Wang, Xiuli Wu, Qiangsheng Zhang, Wei Wei, Xingping Su, Hualong He, Shuyan Zhou, Rong Hu,[...]. J Med Chem 2021
32
25

Quantifying CDK inhibitor selectivity in live cells.
Carrow I Wells, James D Vasta, Cesear R Corona, Jennifer Wilkinson, Chad A Zimprich, Morgan R Ingold, Julie E Pickett, David H Drewry, Kathryn M Pugh, Marie K Schwinn,[...]. Nat Commun 2020
20
12

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
Wei-Gang Tong, Rong Chen, William Plunkett, David Siegel, Rajni Sinha, R Donald Harvey, Ashraf Z Badros, Leslie Popplewell, Steven Coutre, Judith A Fox,[...]. J Clin Oncol 2010
160
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.